ClinicalTrials.gg
TerminatedNCT01100866Updated Mar 11, 2014

Study of POMELLA™ Extract to Treat Prostate Cancer

An interventional study of POMELLA™ (pomegranate extract) and Placebo in Prostate Cancer, sponsored by Vancouver Coastal Health. Terminated at 1 site in Canada. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2014-03-11.

Sponsored by Vancouver Coastal Health · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
due to slow enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 713 studies in Prostatic Neoplasms with a site in Canada — 119 open to participants now, 223 under way, 64 of them phase 3. Prostatic Neoplasms · Canada.

Enrollment
624th of 636
1 · median 100
Started
2010
with 23 others
No phase
190 of 713
47 open now
Registered
216th of 713
by date

Among the 713 studies in Prostatic Neoplasms with a site in Canada, this one is the 624th largest by enrollment of the 636 interventional ones that give a count, is one of 24 that started in 2010, is one of 190 with no phase, and was the 216th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

119 of the 713 studies in Prostatic Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

114 more — sign in →

All 119 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 19 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 713 studies in Prostatic Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This is a randomized, two-arm, placebo controlled trial to evaluate benefit of treatment using POMELLA™ extract on mechanisms known to drive prostate cancer. This research allows provision for biochemical and histological comparisons to be made between POMELLA™ treated and placebo treated prostate tissues removed from men with organ confined prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • clinically localized Prostate Cancer
  • low and intermediate risk for relapse
  • candidates for radical prostatectomy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men 18 years or older (19 years in BC) with a histologic diagnosis of clinically localized prostate cancer prior to radical prostatectomy as defined by:

    1. Clinical state T1-T2
    2. PSA \<20
    3. Gleason score ≤ 7
  • performance status of 0-1.
  • greater than 10 years.
  • Able to understand and give .
  • Laboratory values must be as follows:

    1. White blood cell count: ≥ 3,000/mm\^3
    2. Absolute granulocyte count: ≥ 1,500/mm\^3
    3. : ≥ 100,000/mm\^3
    4. : ≥ 12g/dL
    5. Serum creatinine: ≤ 1.5 x
    6. : ≤ 2 x ULN
    7. ALT: ≤ 2 x ULN
    8. Serum calcium: ≤ ULN
    9. Total : ≤ 1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  • Patients who are receiving any other therapy.
  • Patients who have received or are receiving any other treatment for their prostate cancer.
  • Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.
  • Dementia or significantly altered mental status that would prohibit the understanding and/or giving of .
  • Histologic evidence of small cell carcinoma of the prostate.
  • Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible for study.
  • Patients who are receiving any androgens, estrogens or progestational agents.
  • Patients with a known to pomegranates or composites of the capsules/placebo: hydroxypropyl methylcellulose, silicon dioxide or aerosol.
  • Patients who are taking any drugs or natural health products which might impact biochemical tests (some examples include: spironolactone, aprepitant, bexarotene, clarithromycin, itraconazole, ketoconazole, St. John's wort). A of 30 days prior to commencing the study would be necessary for these compounds if required.
  • Patients who have chronic active hepatitis.
  • Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Active comparator
    Group 1

    POMELLA™ 2 x 500mg capsule once daily

    Dietary Supplement: POMELLA™ (pomegranate extract)

  • Placebo comparator
    Group 2

    POMELLA™ placebo

    Other: Placebo

Interventions

  • Dietary supplementPomegranateStudies of PomegranatePomegranate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    in a capsule form, 2 x 500mg once daily

    Also known as: POMELLA™

  • OtherPlacebo

    placebo capsules

06

What researchers measure

Primary outcomes

  1. Tissue collection and Bioanalysis of the specimens collected

    Prostate tissue are collected at radical radical prostatectomy. These specimens are used to explore the effects of treatment on the expression of the proliferation markers, enzymes, hormnes, receptors and cell signaling proteins known to influence prostate cancer progression.

    Time frame: Tissue collected on Day 31 (after 30 days of study treatment)

07

Study locations

1 site
  • Vancouver Prostate Centre
    Vancouver, British Columbia V5Z 1M9, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2010
First posted
Apr 9, 2010
Start
Jan 2010
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Mar 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01100866
Lead sponsor
Vancouver Coastal Health
Collaborators
Lotte & John Hecht Memorial Foundation
Responsible party
Dr. Alan I. So (Principal Investigator, Vancouver Coastal Health) — Principal investigator
First posted
Apr 9, 2010
Start date
Jan 2010
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Mar 11, 2014

Study contacts

Alan I So, MD, FRCSC
principal investigator · Vancouver Coastal Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomegranate

Start the discussion